Lightnews — Scholar-powered news

VJOncology @vjoncology.bsky.social · 1d

⭐Christina Fotopoulou, MD, PhD, reports TRUST: primary debulking surgery improved PFS in advanced ovarian cancer, though OS was similar across arms:

🎥 buff.ly/DEDNtYW

#ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate #SurgOnc

TRUST: optimal timing of surgical therapy in advanced ovarian cancer - VJOncology

Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, discusses the TRUST study (NCT02828618), a prospective randomized trial on the...

buff.ly

VJOncology @vjoncology.bsky.social · 2d

⭐ Jason Mouabbi, MD, of @mdanderson.bsky.social, shares an overview of key studies in breast cancer presented at #ASCO25:

🎥 buff.ly/0IeuM2Z

@ascocancer.bsky.social #BCSM #BreastCancer #CTSM #TrialUpdate #ImmunoOnc

ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more - VJOncology

Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of key studies in...

buff.ly

VJOncology @vjoncology.bsky.social · 3d

⭐ Swati Kulkarni, MD, discusses the PROMISE study, assessing presurgical use of conjugated CE/BZA in postmenopausal women with ER-positive DCIS:

🎥 buff.ly/FJvSAAR

@ascocancer.bsky.social #ASCO25 #BreastCancer #CTSM #TrialUpadte #SurgOnc

PROMISE: CE/BZA in postmenopausal, ER+ ductal carcinoma in situ - VJOncology

Swati Kulkarni, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, discusses the Phase II PROMISE study (NCT02694809), which assesses...

buff.ly

VJOncology @vjoncology.bsky.social · 4d

⭐ Fabrice André, MD, PhD, shares KEYNOTE-756 results:

➡️ Adding pembrolizumab to neoadjuvant chemo improved pCR in high-risk ER+/HER2- breast cancer. EFS data pending...

🎥 buff.ly/0R25Yjb

#ESMOBreast25 #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc

KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer - VJOncology

Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses the Phase III KEYNOTE-756 study (NCT03725059) of pembrolizumab with neoadjuvant chemotherapy...

buff.ly

VJOncology @vjoncology.bsky.social · 6d

⭐ Felix Hilpert, MD, stresses that age/frailty shouldn’t preclude ovarian cancer therapy: chemo & surgery can extend survival in older pts:

🎥 buff.ly/MUxPkAI

#ESMOGynae25 #GynOnc #GyncSM

Unmet needs in treating ovarian cancer in geriatric patients - VJOncology

Felix Hilpert, MD, Krankenhaus Jerusalem, Hamburg, Germany, gives an overview of treatment gaps in elderly and frail patients with ovarian...

buff.ly

1

VJOncology @vjoncology.bsky.social · 7d

⭐ Yue Che, MD, shares RAISN trial: ICG-guided sentinel node biopsy is feasible & well tolerated in stage I testicular cancer, aiming to reduce chemo use:

🎥 buff.ly/kF09jHH

#EAU25 #UroOnc #UroSoMe #CTSM #TrialUpdate #TSCsm

RAISN: indocyanine green-guided lymph node dissection in testicular cancer - VJOncology

Yue Che, MD, University Hospital of Duesseldorf, Düsseldorf, Germany, discusses the evolving role of retroperitoneal lymph node dissection and therapy...

buff.ly

1

VJOncology @vjoncology.bsky.social · 8d

⭐ Michael Gnant, MD, FACS, reviews long-term endocrine therapy in HR+ breast cancer: benefit for high-risk pts, ovarian suppression in ASTRRA, & elinzanetant for vasomotor symptoms:

🎥 buff.ly/hfp5orD

@ascocancer.bsky.social #ASCO25 #BreastCancer #BCSM #CTSM #TrialUpdate

Tailoring endocrine therapy: risk-based strategies and symptom management in HR+ breast cancer - VJOncology

Michael Gnant, MD, FACS, Medical University of Vienna, reviews four key studies on long-term endocrine therapy in premenopausal HR+ breast...

buff.ly

1

VJOncology @vjoncology.bsky.social · 9d

🎥 Domenica Lorusso, MD, PhD, reports relacorilant + nab-paclitaxel improved PFS & OS in platinum-resistant ovarian cancer w/ consistent safety:

➡️https://buff.ly/M7ojYej

#ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate

ROSELLA trial: relacorilant plus nab-paclitaxel in ovarian cancer - VJOncology

Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, discusses secondary endpoint findings from the Phase...

buff.ly

VJOncology @vjoncology.bsky.social · 10d

🎥 Peter Albers, MD, comments on PROBASE: men with negative biopsy unlikely to develop prostate cancer within 5 yrs. Doubling PSA values key to refining high-risk group & avoiding overdiagnosis.

➡️ buff.ly/4gKsdFN

#EAU25 #UroOnc #UroSoMe #PCSM #CTSM #TrialUpdate

Updates in the PROBASE study of risk adapted screening for prostate cancer - VJOncology

Peter Albers, German Cancer Research Center (DKFZ), Heidelberg & Heinrich-Heine-University, Düsseldorf, Germany, comments on the PROBASE trial of risk adapted...

buff.ly

VJOncology @vjoncology.bsky.social · 11d

🎥 Alberto Farolfi, MD, reports ctDNA did not align with tissue molecular analysis in the RAMP 201 trial for cervical cancer. Highlights limitations of ctDNA as a reliable biomarker in this setting:

➡️ buff.ly/pQUGuhR

#ESMOGynae25 #GynOnc #Gyncsm

Assessing ctDNA to detect mutations in ovarian cancer in the RAMP 201 trial - VJOncology

Alberto Farolfi, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Dino Amadori, Meldola, Italy, describes the limitations of...

buff.ly

VJOncology @vjoncology.bsky.social · 12d

🎥 Stephen Bagley, MD, MSCE, of @upenn.edu, highlights the potential of CSF collection in brain cancer trials to advance biomarker development.

⭐ Systematic studies collecting tumor tissue, blood & CSF could clarify its role in guiding care

Learn more here ➡️ buff.ly/2aTp3iP

#Oncology #BTSM

The future of assessing brain tumors with CSF-based liquid biopsies - VJOncology

Stephen Bagley, MD, MSCE, University of Pennsylvania, Philadelphia, PA, suggests that integrating cerebrospinal fluid (CSF) collection into therapeutic clinical trials...

buff.ly

1

VJOncology @vjoncology.bsky.social · 13d

🎥 Samer Srour, MB ChB, MS, of @mdanderson.bsky.social, discusses IVS-3001, an autologous CAR T targeting HLA-G in advanced solid tumors. Phase I/IIa trial evaluates safety, PK, and early efficacy:

Watch➡️https://buff.ly/KsUmJh8

@ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc #CTSM #TrialUpdate

Phase I/IIa trial of IVS-3001, a HLA-G-targeting CAR T-cell therapy, in solid tumors - VJOncology

Samer Srour, MB ChB, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on an ongoing Phase...

www.vjoncology.com

1

VJOncology @vjoncology.bsky.social · 14d

🎥Nadia Hindi, MD, highlights challenges in comparing ICIs vs antiangiogenic therapy in ultra-rare sarcomas. Limited data & lack of pure monotherapy cohorts make conclusions difficult—randomized trials are needed:

➡️https://buff.ly/utlNO0r⬅️

@ascocancer.bsky.social #ASCO25 #ImmunoOnc #scmSM

Challenges in comparing checkpoint inhibitors in various sarcoma subtypes - VJOncology

Nadia Hindi, MD, Fundación Jimenez Diaz University Hospital, Madrid, Spain, comments on the limitations of comparing immune checkpoint inhibitors in...

www.vjoncology.com

1

VJOncology @vjoncology.bsky.social · 16d

🎥Cecile Riviere-Cazaux, PhD, highlights the role of CSF-based biomarkers in brain tumor trials. Pairing liquid biopsies with tissue biomarkers may optimize use & benchmarking.

➡️https://buff.ly/I2URhgn⬅️

#BTSM #Oncology

Can CSF biomarkers serve as surrogate endpoints in clinical trials? - VJOncology

Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, comments on the potential of cerebrospinal fluid (CSF)-based biomarkers in clinical trials for...

www.vjoncology.com

VJOncology @vjoncology.bsky.social · 17d

🎥Can biomarkers guide T-DXd use in metastatic breast cancer?

⭐ Paolo Tarantino, MD, of @danafarber.bsky.social
reports:

🔹More HER2 mRNA/protein → longer benefit
🔹High Topo1 → worse outcomes in HER2⁻ disease

➡️https://buff.ly/G4wnu14

@ascocancer.bsky.social #ASCO25 #BreastCancer #BCSM #ImmunoOnc

Predictive biomarkers for T-DXd response in metastatic breast cancer - VJOncology

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, comments on a quantitative pre-treatment evaluation of HER2 and topoisomerase 1 (Topo1)...

buff.ly

1

VJOncology @vjoncology.bsky.social · 20d

🎥 Dr Suneel Kamath from @clevelandclinic.bsky.social addresses cancer research funding disparities: current allocation driven by advocacy.

➡️Proposes burden-based, criteria-driven approach to ensure equity across diseases

Watch🔗https://buff.ly/d2uKbEB

@ascocancer.bsky.social #ASCO25 #Oncology

Reforming cancer research funding allocation into a criteria-based process - VJOncology

Suneel Kamath, MD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, shares his insights on the current funding disparities and the...

buff.ly

1

VJOncology @vjoncology.bsky.social · 21d

🎥Dr Inimfon Jackson from @mdanderson.bsky.social
discusses disparities in chemo acceptance:

➡️Greatest in uninsured/publicly insured & Black patients. Advocates trust-building, early risk ID & informed decision support.

🔗 buff.ly/nttGH5r

@ascocancer.bsky.social #ASCO25 #Oncology

Addressing disparities in chemotherapy acceptance: barriers and potential solutions - VJOncology

Inimfon Jackson, MD, PhD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses disparities in chemotherapy acceptance...

buff.ly

1

VJOncology @vjoncology.bsky.social · 23d

🎥 @janichinmay.bsky.social explores alcohol’s role in cancer mortality:

➡️Calls for age/geography–stratified analyses & focus on mechanisms incl. microbiome & ICI interaction.

Learn more here🔗 buff.ly/zcvqHJd

@ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc

Addressing the escalating impact of alcohol on cancer outcomes - VJOncology

Chinmay Jani, MBBS, Sylvester Comprehensive Cancer Center, Doral, FL, comments on the potential relationship between alcohol consumption and cancer mortality,...

buff.ly

VJOncology @vjoncology.bsky.social · 24d

🎥 Xiaoqian Nie, PhD, reports Phase I data:

➡️Erythrocyte–antibody conjugates show stronger antitumor activity & better safety vs PD-1 antibodies in checkpoint-refractory cancers. Promising novel IO strategy

🔗 buff.ly/cD7UDXr

@ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc #CTSM #TrialUpdate

Evaluating erythrocyte-antibody conjugates in solid tumors - VJOncology

Xiaoqian Nie, PhD, Westlake University, Hangzhou, China, shares results of a Phase I trial (NCT06026605) investigating erythrocyte-antibody conjugates in cancers...

buff.ly

VJOncology @vjoncology.bsky.social · 25d

🎥 Dr John Paul Shen (@mdanderson.bsky.social) compares methylation-based tissue-free ctDNA assays vs tissue-reliant approaches.

➡️ Sensitivity varies by tumor site & mutation profile—trials needed to define accuracy in MRD detection.

🔗 buff.ly/cGkX0l2

@ascocancer.bsky.social #ASCO25 #Oncology

Tissue-free versus tissue-reliant ctDNA testing in solid tumors - VJOncology

John Paul Shen, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, compares recent methylation-based tissue free testing...

buff.ly

VJOncology @vjoncology.bsky.social · 26d

🎥 Prof. Francois Doz (@institutcurie.bsky.social) emphasizes precision medicine in pediatric cancer

➡️Trials like iMATRIX Alectinib show promise, but rapid molecular profiling at diagnosis remains a barrier to real-world adoption.

🔗 buff.ly/qJueBU3

@ascocancer.bsky.social #ASCO25 #Oncology #CTSM

Precision medicine in pediatric cancer treatment - VJOncology

Francois Doz, MD, Institut Curie, Paris, France, emphasizes the potential of precision medicine in pediatric cancers, particularly in cases like...

buff.ly

1 2

VJOncology @vjoncology.bsky.social · 27d

🎥 Manmeet Ahluwalia, MD, notes the shift in brain metastasis care: from surgery & WBRT ➡️ targeted therapies & ICIs. Next: combinations with ADCs + ICIs while balancing radiation toxicity.

🔗 buff.ly/Q988SOT

@ascocancer.bsky.social #ASCO25 #ImmunoOnc #Oncology #SurgOnc

The emergence of targeted therapies and ICIs for brain metastasis - VJOncology

Manmeet Ahluwalia, MD, MBA, FASCO, Baptist Health South Florida, Miami, FL, provides an overview of the evolving treatment landscape for...

buff.ly

VJOncology @vjoncology.bsky.social · 28d

🎥 Mario Perro, PhD, highlights GRC 65327, a selective Cbl-b inhibitor:

🚀 Boosts T/NK cell activity, restores T cell function & enhances anti–PD-1 responses in solid tumor models. Favorable safety profile supports further study

🔗 buff.ly/hBycSv4

@theaacr.bsky.social #AACR25 #Oncology #ImmunoOnc

First-in-class Cbl-b inhibitor GRC 65327 in solid tumors - VJOncology

Mario Perro, PhD, Ichnos Glenmark Innovation, New York, NY, discusses the preclinical profile of GRC 65327, a highly selective and...

buff.ly

VJOncology @vjoncology.bsky.social · 29d

🎥 Manas Pustake, MD, highlights disparities in cancer screening access for LGBTQ+ populations vs. non-LGBTQ+ groups in the US, emphasizing the need for targeted interventions:

➡️ buff.ly/5ti0xQr ⬅️

@ascocancer.bsky.social #ASCO25 #Oncology

Disparities in cancer screening among LGBTQ+ populations in the US - VJOncology

Manas Pustake, MD, Texas Tech University Health Science Center, El Paso, TX, comments on the significant disparities in cancer screening...

buff.ly

VJOncology @vjoncology.bsky.social · Sep 7

🎥 Valentina Marulanda Corzo, MD, discusses findings from early-phase trials assessing baseline and follow-up PSMA PET parameters in patients with mCRPC treated with 225Ac-J591:

➡️ buff.ly/777PV9f ⬅️

@ascocancer.bsky.social #ASCO25 #PCSM #UroOnc #UrsoSoMe #TrialUpdate #CTSM

PSMA PET predictors of response to 225Ac-J591 in mCRPC - VJOncology

Valentina Marulanda Corzo, MD, Weill Cornell Medicine, New York, NY, discusses findings from early-phase trials (NCT03276572, NCT04506567, NCT04886986, NCT04946370) assessing...

buff.ly